Standard & Poor’s Ratings Services lowered Valeant Pharmaceuticals’ corporate credit rating after a large holder called a default as a result of the Canadian drugmaker’s failure to file its annual report earlier this year.
from WSJ.com: US Business http://ift.tt/1RVJM6X
via IFTTT
No comments:
Post a Comment